CTLA4 and inflammatory bowel disease: In a study of 102 IBD patients (17% treated with ipilimumab), anti-CTLA4 therapy showed a non-significant but clinically relevant trend toward increased gastrointestinal toxicity in multivariate analysis (p=0.58), while demonstrating significance in univariate analysis (30).